Literature DB >> 22364756

Side-effects of roflumilast.

Steve Gupta.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22364756     DOI： 10.1016/S0140-6736(12)60304-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  14 in total

1.  Response.

Authors:  Jason Rho; Nancy Ho; Vinay Prasad
Journal:  Chest       Date:  2015-07       Impact factor: 9.410

2.  Economics that heals.

Authors:  Lawrence Grouse
Journal:  J Thorac Dis       Date:  2014-06       Impact factor: 2.895

3.  Open access medical publications.

Authors:  Lawrence Grouse
Journal:  J Thorac Dis       Date:  2014-06       Impact factor: 2.895

4.  Counterpoint: were industry-sponsored roflumilast trials appropriate? No.

Authors:  Jason Rho; Nancy Ho; Vinay Prasad
Journal:  Chest       Date:  2014-05       Impact factor: 9.410

5.  Inhibition of Recruitment and Activation of Neutrophils by Pyridazinone-Scaffold-Based Compounds.

Authors:  Aurélie Moniot; Julien Braux; Renaud Siboni; Christine Guillaume; Sandra Audonnet; Ingrid Allart-Simon; Janos Sapi; Rabindra Tirouvanziam; Stéphane Gérard; Sophie C Gangloff; Frédéric Velard
Journal:  Int J Mol Sci       Date:  2022-06-29       Impact factor: 6.208

Review 6.  Phosphodiesterases as therapeutic targets for Alzheimer's disease.

Authors:  Ana García-Osta; Mar Cuadrado-Tejedor; Carolina García-Barroso; Julen Oyarzábal; Rafael Franco
Journal:  ACS Chem Neurosci       Date:  2012-10-01       Impact factor: 4.418

7.  Aspirin Use and Respiratory Morbidity in COPD: A Propensity Score-Matched Analysis in Subpopulations and Intermediate Outcome Measures in COPD Study.

Authors:  Ashraf Fawzy; Nirupama Putcha; Carrie P Aaron; Russell P Bowler; Alejandro P Comellas; Christopher B Cooper; Mark T Dransfield; MeiLan K Han; Eric A Hoffman; Richard E Kanner; Jerry A Krishnan; Wassim W Labaki; Robert Paine; Laura M Paulin; Stephen P Peters; Robert Wise; R Graham Barr; Nadia N Hansel
Journal:  Chest       Date:  2018-12-26       Impact factor: 9.410

8.  Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4).

Authors:  Ryan T Cameron; Ryan G Coleman; Jon P Day; Krishna C Yalla; Miles D Houslay; David R Adams; Brian K Shoichet; George S Baillie
Journal:  Biochem Pharmacol       Date:  2013-03-05       Impact factor: 5.858

Review 9.  Positioning new pharmacotherapies for COPD.

Authors:  Igor Z Barjaktarevic; Anthony F Arredondo; Christopher B Cooper
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-07-24

Review 10.  Pathophysiology and clinical implications of pulmonary arterial enlargement in COPD.

Authors:  J Michael Wells; Mark T Dransfield
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.